RDHL — Redhill Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $2.67m
- -$1.59m
- $8.04m
- 52
- 48
- 16
- 32
Annual cashflow statement for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -76.2 | -97.7 | -71.7 | 23.9 | -8.27 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 10.4 | 15.7 | 26.3 | -46.1 | -3.77 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.42 | -1.15 | 8.01 | -15.6 | 2.05 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -48.6 | -65 | -29.2 | -35.8 | -9.37 |
| Capital Expenditures | -53.8 | -0.115 | -0.198 | -0.011 | -0.009 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 18.1 | -8.03 | 8.5 | 0.015 | 0 |
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -35.6 | -8.14 | 8.3 | 0.004 | -0.009 |
| Financing Cash Flow Items | -16 | -7.4 | -10.9 | 8.65 | 0.79 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 84.4 | 73.5 | 11.5 | 21.4 | 8.42 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.272 | 0.179 | -9.51 | -14.4 | -0.952 |